SSY Group secures 12 products in national centralized medicines procurement

SSY Group Limited announced today that a total of 12 of its products, encompassing 14 specifications, were selected in the eleventh batch of China's National Centralized Medicines Procurement. This significant selection was confirmed on October 27, 2025, bolstering the company's market position.

The selected products include a diverse range of pharmaceuticals, such as Diprophylline Injection (2ml:0.3g), Formoterol Fumarate Inhalation Solution (2ml:20µg), Fluvoxamine Maleate Tablets (100mg and 50mg), Lornoxicam for Injection (8mg), and Epinephrine Hydrochloride Injection (1ml:1mg). Other selected items are Bromhexine Hydrochloride Injection (2ml:4mg), Multiple Electrolyte Injection (500ml), Multiple Electrolyte Injection (II) (500ml and 1000ml), Nicorandil Tablets (5mg), Salbutamol Sulfate Injection (1ml:0.5mg), Benidipine Hydrochloride Tablets (8mg), and Sodium Bicarbonate Injection (50ml:4.2g).

This announcement by the SSY Group board aims to keep shareholders and potential investors informed about the latest business developments, highlighting the group's continued growth and success in securing national procurement contracts.